evaluate the pharmaceuticals company zepbound on glp-1 medications comparison Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 GLP-1 Agonists Market Report 2025-2033,

10.7861/clinmed.2023-0168 5

GLP-1 has a plasma half-life of a few minutes due to proteolytic degradation by the serine protease, dipeptidyl peptidase-IV (DPP-IV), which cleaves the N-terminal histidine and alanine residues from GLP-1 to generate GLP-1 937 and GLP-1 936 amide

Ellingsgaard H, Hauselmann I, Schuler B, et al

This very short action limited the initial enthusiasm for the possible usefulness of incretins for the treatment of T2DM, and in turn stimulated the development of both GLP1 agonists resistant to DPP-4, with a longer half-life and of DPP-4 inhibitors that prolong the half-life of native incretins